Immunology and Molecular Genetics Laboratory, Department of Pathological Sciences, Biologic Science Center, Londrina State University, Paraná, Brazil
Correspondence: Karen Brajão de Oliveira. Department of Pathological Sciences, Biological Sciences Center, State University of Londrina, CEP 86051-970 Londrina, PR, Brazil
- Mots-clés : TGF-β1 polymorphisms, EMSA, luciferase, haplotype, clinical implications
- DOI : 10.1684/ecn.2016.0382
- Page(s) : 81-9
- Année de parution : 2016
Transforming Growth Factor β (TGF-β) is a multifunctional cytokine that plays a role in several biological processes. TGF-β1 is the most abundantly expressed isoform, associated with susceptibility to various diseases, and several polymorphisms have been described in the TGF-β1 gene structure, and some of them have been associated with functional implications. To date, eight single-nucleotide polymorphisms (SNPs) and one deletion/insertion polymorphism have been shown to affect TGF-β1 expression (rs2317130, rs11466313, rs1800468, rs1800469, rs11466314, rs1800471, rs1800470, and rs11466316); some of these interfere with transcriptional regulation by affecting the binding of transcription factors binding, while others interfere with protein production. These polymorphisms have been associated with different types of diseases (i.e., cancers, cardiac diseases, inflammatory diseases, and others) and could therefore be used as susceptibility biomarkers. Since polymorphism clusters are likely to be more reliable than single polymorphisms in this respect, it is hoped that haplotype analysis of TGF-β1 may reveal the genetic basis of disease susceptibility associated with the TGF-β1 gene.